First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus
Article in Antimicrobial Agents and Chemotherapy (March 2024)
The most recent citing publications are shown below. View all 29 publications that cite this research output on Dimensions.
First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus
Preprint in medRxiv (January 2024)
Species-specific MARCO-alphavirus interactions dictate chikungunya virus viremia
Article in Cell Reports (April 2023)